Erasca, Inc. (ERAS)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
17.90 USD
-0.63
(-3.400%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 17.60 -0.30 (-0.301%) ⇩ (July 13, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 7 a.m. EDT
The investment case for Erasca is currently defined by severe distress rather than opportunity. Fundamentally, the company is trapped in a multi-year freefall, having lost over 90% of its value since 2021, with negative earnings, negative cash flow, and a massive market capitalization loss. While the balance sheet shows low debt relative to assets, the business is burning cash with no revenue, making it a classic value trap where the low price reflects a deteriorating reality, not a bargain. The recent price action shows a fragile, volatile recovery attempt, but the underlying fundamentals remain broken. Short-term, the stock is a defensive play rather than a momentum trade. The overwhelming presence of put options suggests investors are hedging against further collapse, while the statistical forecast leans slightly negative. There is no clear catalyst to drive a sustained rally yet. Long-term, the outlook is bleak. The company lacks a proven commercial product, generates no income, and faces significant legal headwinds including a securities class action lawsuit. Without a successful clinical trial readout or a major partnership deal to reverse the bleeding, the equity is likely to remain depressed or face further dilution. This is a speculative bet on a binary event, not a sound investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.174096 |
| AutoETS | 0.270768 |
| AutoTheta | 0.270861 |
| MSTL | 0.325968 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.255 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 11.677 |
| Market Cap | 5,566,623,232 |
| Forward P/E | -32.18 |
| Beta | 0.67 |
| Website | https://www.erasca.com |
As of July 11, 2026, 7 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, with open interest concentrated entirely in out-of-the-money puts across nearly all expirations. Call activity is minimal and skewed toward deep out-of-the-money strikes, indicating a lack of near-term bullish conviction despite some speculative long-dated call buying.
| Attribute | Value |
|---|---|
| 52 Week Change | 11.691781 |
| Address1 | 3,115 Merryfield Row |
| Address2 | Suite 300 |
| All Time High | 24.47 |
| All Time Low | 1.01 |
| Ask | 22.56 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 6,267,580 |
| Average Daily Volume3 Month | 6,888,137 |
| Average Volume | 6,888,137 |
| Average Volume10Days | 6,267,580 |
| Beta | 0.665 |
| Bid | 13.26 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.266 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 17.9 |
| Current Ratio | 9.518 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 18.5 |
| Day Low | 17.632 |
| Debt To Equity | 11.677 |
| Display Name | Erasca |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -130,678,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -41.084 |
| Enterprise Value | 5,368,788,480 |
| Eps Current Year | -0.95948 |
| Eps Forward | -0.55628 |
| Eps Trailing Twelve Months | -0.9 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.3725 |
| Fifty Day Average Change | 4.527499 |
| Fifty Day Average Change Percent | 0.33856788 |
| Fifty Two Week Change Percent | 1,169.1781 |
| Fifty Two Week High | 24.28 |
| Fifty Two Week High Change | -6.380001 |
| Fifty Two Week High Change Percent | -0.26276773 |
| Fifty Two Week Low | 1.33 |
| Fifty Two Week Low Change | 16.57 |
| Fifty Two Week Low Change Percent | 12.458646 |
| Fifty Two Week Range | 1.33 - 24.28 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,442,200,000 |
| Float Shares | 207,890,056 |
| Forward Eps | -0.55628 |
| Forward P E | -32.17804 |
| Free Cashflow | -212,711,744 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 103 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10658 |
| Held Percent Institutions | 0.9355 |
| Implied Shares Outstanding | 310,984,542 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-16 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California. |
| Long Name | Erasca, Inc. |
| Market | us_market |
| Market Cap | 5,566,623,232 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_595471999 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -277,020,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,762,543,563 |
| Number Of Analyst Opinions | 10 |
| Open | 18.44 |
| Operating Cashflow | -91,283,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 858 465 6511 |
| Post Market Change | -0.30130005 |
| Post Market Change Percent | -1.6832405 |
| Post Market Price | 17.5987 |
| Post Market Time | 1,783,987,192 |
| Previous Close | 18.53 |
| Price Eps Current Year | -18.65594 |
| Price Hint | 2 |
| Price To Book | 14.13902 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.267 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.6 |
| Region | US |
| Regular Market Change | -0.630001 |
| Regular Market Change Percent | -3.3999 |
| Regular Market Day High | 18.5 |
| Regular Market Day Low | 17.632 |
| Regular Market Day Range | 17.632 - 18.5 |
| Regular Market Open | 18.44 |
| Regular Market Previous Close | 18.53 |
| Regular Market Price | 17.9 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 2,339,365 |
| Return On Assets | -0.17920999 |
| Return On Equity | -0.69864 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 310,984,542 |
| Shares Percent Shares Out | 0.1039 |
| Shares Short | 32,321,195 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 31,891,428 |
| Short Name | Erasca, Inc. |
| Short Percent Of Float | 0.1166 |
| Short Ratio | 5.04 |
| Source Interval | 15 |
| State | CA |
| Symbol | ERAS |
| Target High Price | 30.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 21.0 |
| Target Median Price | 20.5 |
| Total Cash | 243,788,000 |
| Total Cash Per Share | 0.784 |
| Total Debt | 45,953,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.648575 |
| Two Hundred Day Average Change | 8.251425 |
| Two Hundred Day Average Change Percent | 0.85519624 |
| Type Disp | Equity |
| Volume | 2,339,365 |
| Website | https://www.erasca.com |
| Zip | 92,121 |